Drug-induced glucose and insulin disorders

Year 2014, Volume: 4 Issue: 4, 248 - 252, 03.05.2015

Müge Kökümer Ahmet Özer Şehirli

Abstract

Medications cure the diseases, but sometimes adverse effects occur and these adverse effects cause new diseases. These drug-induced diseases include drug-induced glucose disorders. The clinical significance of drug-induced diseases ranges from negligible to potentially life-threatening. The studies show that there are a few agents implicated in drug-induced glucose disorders. Particularly in patients at risk, health care providers avoid or minimize administration of suspect drugs and monitor the patients. Patients receiving medications that are known to cause drug induced diseases, should be educated about sings and symptoms and advised to consult the health care providers if they experience these signs and symptoms. In patients with new-onset glucose dysfunction, the suspected drugs should be discontinued, if feasible. If the drug can not be discontinued or if the condition does not resolve after discontinuation, a new cure strategy may be required.

Keywords

Drug, diabetes, insulin

İlaca bağlı glukoz ve insülin bozuklukları

Abstract

İlaçlar hastalıkları tedavi ederken bazı durumlarda çeşitli yan etkiler gösterirler ve bu yan etkiler yeni hastalıkların gelişmesine sebep olabilir. Bu ilaca bağlı hastalıklardan bazıları da ilaca bağlı glukoz bozukluklarıdır. Bu hastalıkların zararlı etkileri önemsiz dereceden yaşamı tehdit eden boyutlar arasında değişebilir. Yapılmış çalışmalarla ilaca bağlı glukoz bozukluklarına neden olan pek çok ilaç tespit edilmiştir. Özellikle risk altındaki hastalarda bu ilaçların kullanımından kaçınılmalı, kullanımı en aza indirilmeli veya kişi gözlem altında tutulmalıdır. Ortaya çıkabilecek hastalığın belirti ve semptomları konusunda hasta eğitilmeli, bu tarz belirti ve semptomlar gördüğünde bir sağlık kuruluşuna başvurması gerektiği söylenmelidir.

Keywords

İlaç, diyabet, insülin

References

• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients—a meta-analysis of prospective studies. JAMA 1998;279: 1200-1205.
• Wei X, Ke B, Zhao Z, Ye X, Gao Z, Ye J. Regulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice. PLoS One. 2014; 9: e95399.
• Laughlin MR. Normal Roles for Dietary Fructose in Carbohydrate Metabolism. Nutrients. 2014;6: 3117-3129.
• Dang DK, Pucino F, Ponte CD, Calis KA. Glucose and insulin dysregulation. In: Tisdale JE, Miller DA, eds. Drug-induced diseases. American Society of Health-System Pharmacists, Bethesda: 2010. p.571-585.
• Luna B, Feinglos MN. Drug-induced hyper-glycemia. JAMA 2001; 286:1945-1948.
• Cooper-DeHoff RM, Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST, Gong Y, Hall K, Parekh V, Chapman AB, Boerwinkle E, Johnson JA. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010; 55:61-68.
• Ribeiro MC, Avila DS, Barbosa NB, Meinerz DF, Waczuk EP, Hassan W, Rocha JB. Hydrochlorothiazide and high-fat diets reduce plasma magnesium levels and increase hepatic oxidative stress in rats. Magnes Res. 2013; 26: 32-40.
• Lean MEJ, Pajonk F-G. Patients on atypical antipsychotic drugs. Diabetes Care 2003; 26:1597-1605.
• Mahmoud R, Gianfrancesco F, Grogg A, Nasrallah HA. Differential effects of antipsychotics on type 2 diabetes: findings from a large health plan database. In Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, Dec. 10-14, 2001. p. 199
• Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15:469-474.
• Kallock E, Neher JO, Safranek S. Clinical inquiries: do intra-articular steroid injections affect glycemic control in patients with diabetes? J Fam Pract 2010; 59:709-710.
• Mora PF. Post-transplantation diabetes mellitus. Am J Med Sci 2005; 329:86-94.
• Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19:1411-1418.
• Dumler F, Kilates C. Metabolic and nutritional complications of renal transplantation. J Ren Nutr 2007; 17:97-102.
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [article online]. Available from http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 22 April 2011.
• Morris AD, Boyle DI, McMahon AD, Pearce H, Evans JM, Newton RW, Jung RT, MacDonald TM. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. Diabetes Care 1997; 20:1363-1367.
• Weathermon R, Crabb DW. Alcohol and medication interactions. Alcohol Res Health 1990,23:40-54.
• White JR, Campbell RK. Dangerous and common drug interactions in patients with diabetes mellitus. Endocrinol Metab Clin North Am 2000; 29:789-802.
• White JR, Campbell RK. Drug-drug and drug-disease interactions and diabetes. Diabetes Educ 1995; 21:283-289.
• Murad MH, Coto-Yglesias F, Wang AT, Sheidaee N, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. Clinical review: Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab. 2009; 94: 741-745.
• Lodise T, Graves J, Miller C, Mohr JF, Lomaestro B, Smith RP. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. Pharmacotherapy. 2007; 11:1498-1505.
• Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J 1901;1:760-762.
• Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152:346-357.
• Spivak B, Alamy SS, Jarskog LF, Sheitman BB, Lieberman JA. Ziprasidone alternative for olanzapine-induced hyperglycemia. Am J Psychiatr. 2002;159:1606.
• Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002;31: 257-275.